Comparative Pharmacology
Head-to-head clinical analysis: DALMANE versus PROSOM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALMANE versus PROSOM.
DALMANE vs PROSOM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptor, enhancing GABA inhibitory effects, leading to increased chloride ion influx, hyperpolarization, and sedation.
GABAA receptor agonist, potentiates GABAergic inhibition
15-30 mg orally at bedtime; maximum 30 mg/day.
0.5 mg orally once daily at bedtime for insomnia; maximum dose 1 mg.
None Documented
None Documented
Terminal elimination half-life is 47-100 hours (mean 75 h) in adults; prolonged in elderly (up to 160 h) and cirrhosis (up to 200 h).
Terminal elimination half-life is approximately 20–30 hours (mean 25 h) in adults. Clinically, this supports once-daily dosing with potential for accumulation with repeated administration.
Renal excretion of metabolites (~90%) and unchanged drug (<1%); fecal excretion (~1-2%).
Renal: 80% as metabolites, primarily conjugated; unchanged drug <1%. Fecal: 15%. Biliary: minor.
Category C
Category C
Benzodiazepine Hypnotic
Benzodiazepine Hypnotic